The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice

Anna Maria Malfitano, Chiara Laezza, Mario Galgani, Giuseppe Matarese, Alba D'Alessandro, Patrizia Gazzerro, Maurizio Bifulco

Research output: Contribution to journalArticle

Abstract

Emerging findings suggested the efficacy of the cannabinoid CB1 receptor antagonist rimonabant (SR141716) in several pathological conditions included tumours. In this study we investigated in vitro the effects of SR141716 on viability and the molecular pathways of methylcholanthrene-induced fibrosarcoma (Meth-A) cells and in vivo its anti-tumour properties in Meth-A-bearing mice. We evaluated in vitro the effect of SR141716 on Meth-A cell viability by trypan blue staining assay. Cell cycle progression and apoptosis were assessed by flow cytometry. Protein expression was investigated by Western blot. The anti-tumour efficacy of SR141716 was evaluated in vivo monitoring weight increase and survival of Meth-A injected mice. SR141716 affects Meth-A cell viability inducing apoptosis and controls cell cycle progression by modulation of the levels of the cell cycle inhibitor p21waf, cyclins E, D1 and NF-kB molecules. Importantly, SR141716 affects AKT/pFoxO1 pathway which promotes cell survival and regulates the cell cycle. The molecular effects observed are accompanied by reduced COX2 expression and induction of the CB1 receptor expression. Finally, SR141716 was able to reduce the tumour size and prolong animal survival, when administered in vivo during tumour growth. Our findings shed light on a novel molecular pathway associated with control of tumour growth by SR141716 and confirm the anti-cancer and anti-inflammatory properties of this drug suggesting its potential applications in the treatment of cancer.

Original languageEnglish
Pages (from-to)365-371
Number of pages7
JournalPharmacological Research
Volume65
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

rimonabant
Cannabinoid Receptor CB1
Cell Survival
Methylcholanthrene
Fibrosarcoma
Growth
Neoplasms
Cell Cycle
Cannabinoid Receptor Antagonists
Apoptosis
Cyclin E
Trypan Blue
NF-kappa B
Cyclin D1

Keywords

  • Animal model
  • Anti-tumour effect
  • Ascites
  • CB1 antagonist

ASJC Scopus subject areas

  • Pharmacology

Cite this

Malfitano, A. M., Laezza, C., Galgani, M., Matarese, G., D'Alessandro, A., Gazzerro, P., & Bifulco, M. (2012). The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice. Pharmacological Research, 65(3), 365-371. https://doi.org/10.1016/j.phrs.2011.11.008

The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice. / Malfitano, Anna Maria; Laezza, Chiara; Galgani, Mario; Matarese, Giuseppe; D'Alessandro, Alba; Gazzerro, Patrizia; Bifulco, Maurizio.

In: Pharmacological Research, Vol. 65, No. 3, 03.2012, p. 365-371.

Research output: Contribution to journalArticle

Malfitano, AM, Laezza, C, Galgani, M, Matarese, G, D'Alessandro, A, Gazzerro, P & Bifulco, M 2012, 'The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice', Pharmacological Research, vol. 65, no. 3, pp. 365-371. https://doi.org/10.1016/j.phrs.2011.11.008
Malfitano AM, Laezza C, Galgani M, Matarese G, D'Alessandro A, Gazzerro P et al. The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice. Pharmacological Research. 2012 Mar;65(3):365-371. https://doi.org/10.1016/j.phrs.2011.11.008
Malfitano, Anna Maria ; Laezza, Chiara ; Galgani, Mario ; Matarese, Giuseppe ; D'Alessandro, Alba ; Gazzerro, Patrizia ; Bifulco, Maurizio. / The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice. In: Pharmacological Research. 2012 ; Vol. 65, No. 3. pp. 365-371.
@article{29ea5d0bb0054368ab938c7af0c2f2c1,
title = "The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice",
abstract = "Emerging findings suggested the efficacy of the cannabinoid CB1 receptor antagonist rimonabant (SR141716) in several pathological conditions included tumours. In this study we investigated in vitro the effects of SR141716 on viability and the molecular pathways of methylcholanthrene-induced fibrosarcoma (Meth-A) cells and in vivo its anti-tumour properties in Meth-A-bearing mice. We evaluated in vitro the effect of SR141716 on Meth-A cell viability by trypan blue staining assay. Cell cycle progression and apoptosis were assessed by flow cytometry. Protein expression was investigated by Western blot. The anti-tumour efficacy of SR141716 was evaluated in vivo monitoring weight increase and survival of Meth-A injected mice. SR141716 affects Meth-A cell viability inducing apoptosis and controls cell cycle progression by modulation of the levels of the cell cycle inhibitor p21waf, cyclins E, D1 and NF-kB molecules. Importantly, SR141716 affects AKT/pFoxO1 pathway which promotes cell survival and regulates the cell cycle. The molecular effects observed are accompanied by reduced COX2 expression and induction of the CB1 receptor expression. Finally, SR141716 was able to reduce the tumour size and prolong animal survival, when administered in vivo during tumour growth. Our findings shed light on a novel molecular pathway associated with control of tumour growth by SR141716 and confirm the anti-cancer and anti-inflammatory properties of this drug suggesting its potential applications in the treatment of cancer.",
keywords = "Animal model, Anti-tumour effect, Ascites, CB1 antagonist",
author = "Malfitano, {Anna Maria} and Chiara Laezza and Mario Galgani and Giuseppe Matarese and Alba D'Alessandro and Patrizia Gazzerro and Maurizio Bifulco",
year = "2012",
month = "3",
doi = "10.1016/j.phrs.2011.11.008",
language = "English",
volume = "65",
pages = "365--371",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "3",

}

TY - JOUR

T1 - The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice

AU - Malfitano, Anna Maria

AU - Laezza, Chiara

AU - Galgani, Mario

AU - Matarese, Giuseppe

AU - D'Alessandro, Alba

AU - Gazzerro, Patrizia

AU - Bifulco, Maurizio

PY - 2012/3

Y1 - 2012/3

N2 - Emerging findings suggested the efficacy of the cannabinoid CB1 receptor antagonist rimonabant (SR141716) in several pathological conditions included tumours. In this study we investigated in vitro the effects of SR141716 on viability and the molecular pathways of methylcholanthrene-induced fibrosarcoma (Meth-A) cells and in vivo its anti-tumour properties in Meth-A-bearing mice. We evaluated in vitro the effect of SR141716 on Meth-A cell viability by trypan blue staining assay. Cell cycle progression and apoptosis were assessed by flow cytometry. Protein expression was investigated by Western blot. The anti-tumour efficacy of SR141716 was evaluated in vivo monitoring weight increase and survival of Meth-A injected mice. SR141716 affects Meth-A cell viability inducing apoptosis and controls cell cycle progression by modulation of the levels of the cell cycle inhibitor p21waf, cyclins E, D1 and NF-kB molecules. Importantly, SR141716 affects AKT/pFoxO1 pathway which promotes cell survival and regulates the cell cycle. The molecular effects observed are accompanied by reduced COX2 expression and induction of the CB1 receptor expression. Finally, SR141716 was able to reduce the tumour size and prolong animal survival, when administered in vivo during tumour growth. Our findings shed light on a novel molecular pathway associated with control of tumour growth by SR141716 and confirm the anti-cancer and anti-inflammatory properties of this drug suggesting its potential applications in the treatment of cancer.

AB - Emerging findings suggested the efficacy of the cannabinoid CB1 receptor antagonist rimonabant (SR141716) in several pathological conditions included tumours. In this study we investigated in vitro the effects of SR141716 on viability and the molecular pathways of methylcholanthrene-induced fibrosarcoma (Meth-A) cells and in vivo its anti-tumour properties in Meth-A-bearing mice. We evaluated in vitro the effect of SR141716 on Meth-A cell viability by trypan blue staining assay. Cell cycle progression and apoptosis were assessed by flow cytometry. Protein expression was investigated by Western blot. The anti-tumour efficacy of SR141716 was evaluated in vivo monitoring weight increase and survival of Meth-A injected mice. SR141716 affects Meth-A cell viability inducing apoptosis and controls cell cycle progression by modulation of the levels of the cell cycle inhibitor p21waf, cyclins E, D1 and NF-kB molecules. Importantly, SR141716 affects AKT/pFoxO1 pathway which promotes cell survival and regulates the cell cycle. The molecular effects observed are accompanied by reduced COX2 expression and induction of the CB1 receptor expression. Finally, SR141716 was able to reduce the tumour size and prolong animal survival, when administered in vivo during tumour growth. Our findings shed light on a novel molecular pathway associated with control of tumour growth by SR141716 and confirm the anti-cancer and anti-inflammatory properties of this drug suggesting its potential applications in the treatment of cancer.

KW - Animal model

KW - Anti-tumour effect

KW - Ascites

KW - CB1 antagonist

UR - http://www.scopus.com/inward/record.url?scp=84857063038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857063038&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2011.11.008

DO - 10.1016/j.phrs.2011.11.008

M3 - Article

C2 - 22123497

AN - SCOPUS:84857063038

VL - 65

SP - 365

EP - 371

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 3

ER -